Ketamine Versus Midazolam as the First-Line Continuous Infusion for Status Epilepticus in Children with Cardiac Disease.

Abstract

Listen

Translate article

The treatment of status epilepticus (SE) in children with cardiac disease is challenging given their often-tenuous hemodynamic state. We aim to determine whether ketamine is safe and effective in children with cardiac disease as the first-line continuous infusion for the treatment of refractory SE (RSE) and to compare ketamine to midazolam for the treatment of RSE in this population. This is a single-center retrospective cohort study of pediatric patients with cardiac disease and RSE admitted to the cardiac intensive care unit at a tertiary children's hospital between January 1, 2017 and June 30, 2023. Consecutive patients < 18 years of age who had electroencephalogram-confirmed RSE treated with a continuous infusion of ketamine and/or midazolam were included. Clinical variables were extracted from the electronic medical record, and descriptive statistics were used. Thirty-four patients with cardiac disease and RSE were treated with a continuous infusion: 15 were treated with ketamine first, and 19 were treated with midazolam first. An equivalent number of patients in both groups required a single infusion for seizure cessation (11 [73%] in the ketamine group and 12 [63%] in the midazolam group; p = 0.72). The median time from seizure onset to seizure cessation, time from seizure onset to initiation of a continuous infusion, time from initiation of a continuous infusion to seizure cessation, infusion duration, and recurrence of seizures during weaning of the continuous infusion were comparable between groups. There was no difference between groups in the proportion of patients who experienced potential adverse events attributable to their continuous infusion. This retrospective cohort study provides evidence that ketamine may be as effective as midazolam as the first-line continuous infusion for RSE in children with cardiac disease. This study also provides preliminary evidence of safety in this population, at least in comparison to midazolam.